Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors

Molecular Therapy

Volumn 4, Issue 3, 2001, Pages 217-222

  Chao, Hengjun ^a   Monahan, Paul E ^a   Liu, Yuanbo ^a   Samulski, R Jude ^a   Walsh, Christopher E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Hemophilia B; Mutant mice; Serotype

Indexed keywords

BLOOD CLOTTING FACTOR 9; CYCLOPHOSPHAMIDE; PROTEIN ANTIBODY; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOG; GENETIC ENGINEERING; HEMOPHILIA B; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; SEROTYPE; SURVIVAL;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CANIS FAMILIARIS;

EID: 0034842912     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0449     Document Type: Article

References (31)

1. Hemophilia and related conditions-inherited deficiencies of prothrombin(factor II), factor V, and factor VII to XII
2. Clinical aspects and therapy for hemophilia B
3. Haemophilia prophylaxis in young patients-a long-term follow-up
4. Adeno-associated viral vectors
5. Persistent expression of canine factor IX in hemophilia B canines
6. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
7. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
8. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors
9. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers
10. A coagulation factor IX-deficient mouse model for human hemophilia B
11. Human factor IX corrects the bleeding diathesis of mice with hemophilia B
12. A tail vein bleeding time model and delayed bleeding in hemophiliac mice
13. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA
14. Stable gene transfer and expression of human coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
15. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX
16. Cyclophosphamide-induced immunological tolerance: An overview
17. The treatment of factor VIII inhibitors-a general overview
18. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
19. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
20. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX
21. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors
22. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
23. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
24. Factor VIII inhibitor treatment with high doses of F VIII
25. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
26. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors
27. Cross-presentation, dendritic cells, tolerance and immunity
28. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
29. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
30. Sustained expression of human factor VIII in mice using a parvovirus-based vector
31. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine